Results 131 to 140 of about 2,974 (211)

Emergence of Dalbavancin, Vancomycin, and Daptomycin Cross-resistance in MRSA During Long-term LVAD Suppression With Vancomycin Followed by Dalbavancin: Genomic Insights and Synergy With Cefadroxil. [PDF]

Open Forum Infect Dis
Stohs EJ, Alexander BT, Fey PD, Foreman MCL, Xu L, Penewit K, Waalkes A, Salipante SJ, Werth BJ.   +8 more
europepmc   +1 more source

Oritavancin for the Treatment of <i>Staphylococcus aureus</i> Bacteremia-A Retrospective Single-arm Cohort Study. [PDF]

Open Forum Infect Dis
Jordan H, Kozierowski K, Pickles R, Davis JS.   +3 more
europepmc   +1 more source

Understanding Daptomycin Resistance Mechanisms and Treatment Challenges in <i>Enterococcus faecium</i> Infection: A Case Series. [PDF]

Antibiotics (Basel)
Nair-Collins S, Godart G, Patel N, Yadav V, Larimore K, LeGout JD, Chitale R, Durvasula R, Oring J.   +8 more
europepmc   +1 more source

A prospective observational cohort study in primary care practices to identify factors associated with treatment failure in skin and soft tissue infections [PDF]

core   +1 more source

Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome? [PDF]

J Antimicrob Chemother
MacPhail A, Attwood LO, Rogers BA.
europepmc   +1 more source

Therapeutic approach to difficult-to-treat multidrug-resistant enterococcal infections. [PDF]

Antimicrob Agents Chemother
Turner AM, Kinsella P, Miller WR, Carter GP, Tran TT, Howden BP, Arias CA.   +6 more
europepmc   +1 more source

Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials. [PDF]

J Antimicrob Chemother
Werth BJ, Zhang R, Barreras Beltran IA, Penewit K, Waalkes A, Holmes EA, Salipante SJ, Xu L.   +7 more
europepmc   +1 more source

UK Antimicrobial Registry: Virtual Registry-an innovative surveillance approach for monitoring the real-world use and effectiveness of newly licensed antimicrobials in Scotland. [PDF]

JAC Antimicrob Resist
Goswami C, Turgal E, Mueller T, Bennie M, Parr R, Jones GT, Seaton RA, Jenkins D, Baltas I, Sneddon J, Sandoe JAT, Garraghan F, Brown NM, Macfarlane GJ, Kurdi A.   +14 more
europepmc   +1 more source

Reply to White and Siegrist, "Multi-drug-resistant enterococcal infections: duration of combination therapy and OPAT challenges". [PDF]

Antimicrob Agents Chemother
Arias CA, Tran TT, Kinsella P, Howden BP, Miller WR.   +4 more
europepmc   +1 more source

Challenges in monitoring vancomycin in outpatient parenteral antimicrobial therapy: opportunities for mitigation utilizing OSHA's framework for mitigating workplace hazards. [PDF]

Antimicrob Steward Healthc Epidemiol
Regli DC, Warner S, Wilcox E, Zimmerman J, Bittner MJ.   +4 more
europepmc   +1 more source